Cited by 88Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesNeurotransmitter Receptor Influence on BehaviorMemory and Neural Mechanisms

Two-Week Treatment With the Selective Serotonin Reuptake Inhibitor Citalopram Reduces Contextual Anxiety but Not Cued Fear in Healthy Volunteers: A Fear-Potentiated Startle Study

Open access
Grillon, Christian, Chavis, Chanen, Covington, Matthew F, Pine, Daniel S·2009·Neuropsychopharmacology

Abstract

Chronic treatment with selective serotonin reuptake inhibitors (SSRIs) alleviates both anxiety symptoms and associated physiologic disturbances in anxious patients. However, limited research considers the degree to which chronic SSRI treatment influences anxiety in healthy individuals. This study examined the effect of 2-week citalopram treatment on two threat responses: short- and long-duration-potentiated startle. Prior work suggests that these two responses provide neurally and functionally distinct models of fear and anxiety, respectively, in rodents. Healthy volunteers (n=53) received either placebo or citalopram (20 mg per day) for 2 weeks under double-blind conditions. They were each tested twice, before and after treatment. Participants were exposed to three conditions, including one in which predictable aversive shocks were signaled by a cue, a second in which unpredictable shocks were anticipated, and a third in which no shocks were administered. Aversive states were indexed by acoustic startle. Phasic fear-potentiated startle to the threat cue, as well as sustained startle potentiation to the experimental context in the predictable and unpredictable conditions, were investigated. Citalopram affected neither baseline startle nor short-duration fear-potentiated startle to discrete threat cues. However, citalopram reduced long-duration startle potentiation in the predictable conditions. These results are consistent with the hypothesis that short- and long-duration aversive states are mediated by distinct neural systems. They suggest that citalopram alleviates symptoms of anticipatory anxiety, not fear, by acting on mechanisms underlying long-duration aversive states.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npp.2008.141

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 37 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Parks CL Robinson PS Sibille E Shenk T Toth M Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci U S A 1998 95 10734 9 9724773 PMC27964

Cited by

Sorted by citations

Authors
Grillon, C., Chavis, C., Covington, M. F., & Pine, D. S.
Affiliations
National Institutes of Health (US)
Corresponding author
Grillon, Christian
Venue
Neuropsychopharmacology
Published
2008-09-17
Volume
34
Issue
4
Pages
964-971
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2091082613
Cited by
88
References
37
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 7 · 2021: 11 · 2020: 4 · 2019: 7 · 2018: 5 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 8 · 2013: 3 · 2012: 5
FWCI
6.36
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health (Z01MH002798)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
Keywords
citalopram, selective serotonin reuptake inhibitors, fear-potentiated startle, anticipatory anxiety, fear, acoustic startle response, threat cues, healthy volunteers
MeSH terms
Acoustic Stimulation, Adult, Analysis of Variance, Anxiety, Cues, Double-Blind Method, Electroshock, Fear, Female, Humans, 5-Hydroxytryptophan, Male, Reflex, Startle, Citalopram, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review